{"id":"sr34006","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CCR2 is a G-protein coupled receptor expressed on monocytes and other immune cells that mediates their migration in response to chemokine ligands. By antagonizing CCR2, SR34006 reduces monocyte infiltration into inflamed tissues, thereby decreasing inflammatory responses. This mechanism has been explored for conditions characterized by excessive monocyte-driven inflammation.","oneSentence":"SR34006 is a selective antagonist of the chemokine receptor CCR2, which blocks the recruitment of monocytes and inflammatory cells to sites of inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:29.878Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic kidney disease"}]},"trialDetails":[{"nctId":"NCT00311090","phase":"PHASE3","title":"Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-04","conditions":"Deep Venous Thrombosis","enrollment":757},{"nctId":"NCT00345618","phase":"PHASE3","title":"Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Embolism, Thrombosis","enrollment":3202},{"nctId":"NCT00580216","phase":"PHASE3","title":"Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-12","conditions":"Atrial Fibrillation","enrollment":3773},{"nctId":"NCT00071279","phase":"PHASE3","title":"SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-11","conditions":"Pulmonary Embolism, Deep Vein Thrombosis","enrollment":1215},{"nctId":"NCT00067093","phase":"PHASE3","title":"Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-05","conditions":"Deep Vein Thrombosis","enrollment":1452},{"nctId":"NCT00070655","phase":"PHASE3","title":"Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-09","conditions":"Atrial Fibrillation","enrollment":4673},{"nctId":"NCT00062803","phase":"PHASE3","title":"SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Pulmonary Embolism","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SR34006","genericName":"SR34006","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SR34006 is a selective antagonist of the chemokine receptor CCR2, which blocks the recruitment of monocytes and inflammatory cells to sites of inflammation. Used for Diabetic kidney disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}